Recordati focuses on the research, development, manufacturing and marketing of pharmaceuticals. The company has operating subsidiaries in France, Ireland, Spain, Switzerland and the US, with a total staff of over 2,400. Recordati promotes a wide range of innovative pharmaceuticals, both proprietary and in-licensed products in the areas of cardiology, respiratory, gastroenterology, CNS, analgesia and anti-infective. The company’s lead products are Zanedip®/Zanidip®/Lercadip® (lercanidipine), a calcium channel blocker for the treatment of hypertension and Elopram®/Entact® for depression and panic disorder. The company had a net income of €23.7 M (US$26.9 M) in 2003.